Oct 03, 2022 / 02:00PM GMT
Kath Gallagher - Avidity Biosciences, Inc. - SVP Corporate Communications & IR
Good morning, everyone. I'm Kath Gallagher, Senior Vice President of Investor Relations and Corporate Communications at Avidity Biosciences. Welcome, and thank you for taking the time to join us today for Volume 4 of our Investor and Analysts event series. Today, we'll be focusing on AOC 1020 and the Phase 1/2 FORTITUDE trials in adults with FSHD.
Before we get started today, we remind everyone that we will be making forward-looking statements based on current expectations that are subject to and covered by the safe harbor protections provided under the Private Securities Litigation Reform Act of 1995, including statements about the initiation and outcomes of clinical trials for our AOC program. These forward-looking statements are not a guarantee of performance, and Avidity's actual results may differ materially from these forward-looking statements as a result of various important factors. Including those discussed in the risk factor section of Avidity's SEC filings, including our most recently filed 10-K and 10-Q
Avidity Biosciences Inc Investor & Analyst Event Series - VOL. 4: Advancing AOC 1020 into the Clinic Call Transcript
Oct 03, 2022
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers